Kinetic Gain · Pharmacovigilance Signal Router
synthetic safety signals · no patient-identifiable or sponsor-confidential data
Biotech / diagnostics safety routing proof C# · patient-safety and regulatory workflow depth Hosted preview planned · Embedded by engagement

Safety signals, routing gaps, and review posture that stay operator-readable.

This control plane turns synthetic pharmacovigilance exports into one review surface: case completeness, seriousness assessment, MedDRA coding, follow-up closure, aggregate reporting evidence, and named signal actions before committee decisions harden around weak packets.

Operator Snapshot

biotech · diagnostics · safety signal routing
3
signal clusters
Synthetic adverse-event and literature signal clusters across active safety lanes.
2
current lanes
Two lanes are current enough to route without a freshness refresh.
6
open gaps
Intake, seriousness, coding, reporting, follow-up, and signal-review gaps stay visible.
4
escalation blocks
Four issues still block clean escalation or committee closure.
3
evidence risks
Case intake, seriousness assessment, and MedDRA coding still need repair.
3
reporting risks
Follow-up, aggregate reporting, and signal review are not committee-safe yet.

Why this lane matters

biotech / diagnostics / csharp
safety confidence
Stop weak signal packets from slipping into committee review

Safety teams need one board where intake completeness, medical seriousness review, MedDRA coding, follow-up closure, aggregate reporting evidence, and named signal actions stay readable together.

founder edge
Enterprise routing and evidence posture, applied to drug-safety work

This follows the Kinetic Gain pattern: routing, evidence, approvals, and operator-safe remediation posture for review-critical safety workflows.

monetization path
Hosted preview planned · Embedded by engagement

The free surface proves the operator model; the commercial path is an embedded safety-signal router for regulated pharmacovigilance teams.